Omar Amirana is a Senior Vice President for Allied Minds and currently is the CEO of SciFluor and LuxCath. Omar previously served as a Partner at Oxford Bioscience Partners, a Boston-based venture capital firm with ~$1B under management. There he sourced and led the Series A investment in nFocus Neuromedical which commercialized a catheter-based aneurysm therapy and was recently sold to Covidien for ~$100M. He has served on the boards of Flowmedica (renal therapy; sold to AngioDynamics), SmartPill (GI capsule technology; sold to Given Imaging), Coherex (catheter closure of LAA and PFO), Mitralign (percutaneous heart valve repair), and Cambridge Endoscopic Devices (articulating laparoscopic surgical tools). He was the co-founder of Cardima (AF ablation; IPO) and Resolution Medical (cardiac mapping) based in Silicon Valley. He was also the VP of Marketing of MedicaLogic/Medscape, (EMR/HCIT), and served as VP of Business Development at St. Jude Medical (STJ, $5.2B in revenue).
He has developed and launched products worldwide. He is currently on the board of Cardiofocus (AF catheter ablation) as well as the Ignition Awards Committee at Boston University. He previously served on the Oversight Committee for the Coulter Translational Research Partnership at Columbia University. As a co-founder of Propel Careers, he is passionate about helping aspiring entrepreneurs in life sciences. Omar earned a BS in Mechanical Engineering from Tufts University and an MD from Eastern Virginia Medical School.
PJ Anand founded Alcyone Lifesciences, Inc. in 2010 to address the large unmet need in treatment of difficult neuropathological conditions. PJ brings more than 18 years of operational, business and corporate development experience to Alcyone Lifesciences. Prior to Alcyone, he was a founding executive and Executive Vice President of Corporate Development at Arsenal Medical, Inc. As EVP of corporate development, PJ was responsible for leading Arsenal’s corporate strategy and business development activities with pharmaceutical / biotechnology, and medical device companies including technology in-licensing, out-licensing and strategic alliances. Prior to this role, he has served as the Company’s Vice President of Business and Commercial Development and working closely with Arsenal’s technology visionaries, operational team and founding scientists played a critical role in creation of Arsenal’s platform and product portfolio. Prior to joining Arsenal in 2005, PJ, served as Vice President & General Manager of Spire Biomedical, Inc., a division of Spire Corporation (NASDAQ: SPIR) where he was responsible for establishing a medical products business unit. While at Spire, PJ was responsible for R&D, sales & marketing and business transactions. He was also chiefly responsible for identifying and in-licensing the seminal technology for the company as well as executing major transactions with $1B+ revenue deriving medical device companies that resulted in several million dollars of non-dilutive revenue for the company.
In addition, PJ has served as head of business & strategy for Toxikon Corporation, a CRO focused on providing preclinical strategy and services for pharmaceutical, biotechnology and medical device companies. During his tenure there he led a team that was responsible 250% revenue growth in a span of 3 years. This was a result of execution of creative partnerships with top-tier life sciences companies in pharmaceuticals / biotechnology and medical devices. In addition, he serves as adviser on strategy & business to Claros Diagnostic, Spire Corporation, Neurowave Modulation Technologies and Vyteris Pharmaceuticals as well as non-profit organizations. PJ Anand has a bachelors degree and a master level education in Biochemistry and has several patent pending inventions to his credit.
Dr. Donabedian is a Venture Partner of Longwood Fund. He joins from AbbVie, where as Vice President and Head, Ventures and Early Stage Collaborations he led a global team of business development and investment professionals that made minority investments in biotech companies, licensed or acquired preclinical and Phase 1 compounds and created partnerships with leading academic institutions. Prior to AbbVie, Dr. Donabedian was Senior Vice President at Locust Walk Partners a life sciences consulting firm. Previously, Dr. Donabedian was VP Global New Deal Strategy and Development at GlaxoSmithKline (GSK). Prior to that, he held management positions at Surface Logix and Senior Manager and Accenture's Strategic Services Consulting Group. Dr. Donabedian began his career as a research scientist with Dow Chemical and Boston Scientific. He holds a Bachelor of Arts in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and a Masters of Business Administration from the University of North Carolina at Chapel Hill. He currently serves on the Board of Alcyone Life Sciences, a privately held biotech company he co-founded. He is also a strategic advisor to DNATrix.
Since joining Covington Associates in 1996, Ben has been providing investment banking services in the area of mergers & acquisitions. Ben’s area of specialty is advising medical technology and healthcare services firms.
Ben has successfully orchestrated nearly 100 transactions with companies such as Bard, Boston Scientific, Cardinal, Cerner, GE, Life Technologies, McKesson, Medtronic, Quintiles, Pall, Sanofi and Siemens. He is also the author of numerous articles, including a white paper on “A Strategic Review of Outsourced Manufacturing for Medical Devices”.
Ben received his undergraduate degree from the University of Vermont and his MBA and Masters degrees from the University of New Mexico.
Bryan Giraudo is a Managing Director in San Francisco, where he is responsible for the Firm’s Western North America biotechnology and medical technology relationships. With nearly twenty years of experience. Bryan has executed more than 100 initial public offerings, follow-on and convertible financing transactions, as well as, product and company buy-side, sell-side and corporate collaboration strategic advisory assignments for biotechnology, specialty pharmaceutical and medical technology clients. Recent transactions include financings for Seattle Genetics, Forward Pharma, Retrophin and Xencor, as well as, the sale of Ambit to Daiichi, Ventana Medical System’s hostile defense and subsequent sale to Roche and the sale of Cougar Biotechnology to Johnson & Johnson. Bryan received his B.A. from Georgetown University.
Jason joined Sanofi-Genzyme BioVentures in 2014 with a background in early stage biotech investing and transactions. Prior to SGBV, Jason was the Director of Corporate Development at RaNA Therapeutics, LLC a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group and a Board Observer for several portfolio companies. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space.
Jason currently serves on the Board of Trustees at the Buckingham Browne and Nichols school and on The Board of Directors of The Magdalene College Foundation.
Jason holds a B.A. from Bowdoin College, and Ph.D. from the University of Cambridge.
Paulina Hill is a Principal at Polaris Partners. Paulina joined Polaris in 2011 and focuses on investments in healthcare.
Paulina serves on the boards of Arsenal Medical, Faraday Pharmaceuticals and KinDex Pharmaceuticals and is an observer on the boards of MicroCHIPS and 480 Biomedical. Paulina also works closely with Arsia Therapeutics, an early-stage Bob Langer-founded startup which she was actively involved in spinning out of MIT. Paulina serves on the board of The Capital Network, a non-profit that provides fundraising education to startup entrepreneurs and is part of the Lead Mentor team for Canadian Entrepreneurs in New England.
Prior to joining Polaris, Paulina completed her postdoctoral fellowship in the Chemical Engineering department at the Massachusetts Institute of Technology. In the laboratory of Bob Langer, Paulina worked on developing novel biomaterial scaffolds and drug delivery systems for neural applications. Paulina is the founding president of the MIT Postdoctoral Association, and served on the MIT Intellectual Property Presidential Committee.
Paulina completed her PhD in Molecular Medicine with a Tissue Engineering focus at Wake Forest University School of Medicine. Her graduate school work resulted in over 40 published abstracts, awards and peer reviewed manuscripts. Her research contributed to numerous patents and the formation of the startup KeraNetics to commercialize the platform technology. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. She attended East Carolina on an athletic scholarship where she was captain of the women’s tennis team.
Luke Timmerman is the founder and editor of Timmerman Report, a subscription publication for biotech insiders. He is also working on his first book, a biography of biotech pioneer Lee Hood. Previously, Luke covered biotech at The Seattle Times, Xconomy, and Bloomberg News. Luke has a bachelor’s in journalism from the University of Wisconsin, and in 2005-2006, he was awarded a Knight Science Journalism Fellowship at MIT. He likes to run marathons and climb mountains.
James Woods is a Principal in PwC's Deals practice in Boston specializing in corporate finance and valuation and is a leader in the Deals Pharmaceutical and Life Sciences sector practice. James has over 12 years of experience in valuation analysis and financial advisory work related to mergers and acquisitions, divestitures, corporate restructurings, capital market transactions, and strategic decision making. James has extensive experience working with companies in the life sciences industry including medical technology, biotechnology, diagnostics and pharmaceutical companies. James received his BS in Management Science with a concentration in Finance, MS in Finance and MBA from Boston College.
Michelle L. Basil is a partner in the Business Department of Nutter, a member of the firm’s Emerging Companies practice group and chair of the Life Sciences practice group. Michelle’s practice focuses on corporate and securities law, including angel and venture capital transactions, public securities offerings, mergers and acquisitions, strategic partnerships and collaborations, licensing, distribution transactions and corporate governance, and equity compensation matters. Michelle represents clients in a broad range of industries, including public and private life sciences, high technology and financial services companies. Michelle serves as outside general counsel to companies in biotechnology, medical devices, diagnostics, and health care services. Michelle received her B.A. and J.D. from the University of California, Berkeley. Michelle is a member of or participates at Boston Harbor Angels, M2D2, MTTC, Launchpad Venture Group, MassBio and MassMEDIC. For Michelle's full Nutter bio, click here.
Jeremy’s practice focuses on private equity, venture capital, and angel financing transactions, mergers and acquisitions, equity and entrepreneurial compensation matters, and general start-up support. As a former entrepreneur, Jeremy spends a large portion of his time on behalf of the firm, connecting with and supporting the entrepreneurial ecosystem in New England. Concurrently, Jeremy serves on the Board of The Capital Network and on the Board of Directors of MassVentures, the venture capital arm of the Commonwealth. Jeremy is also a Professor of Entrepreneurial Leadership at Tufts University, a Connector in the Boston World Partnership, and a proud co-founder of BostonIDEA (helping the entrepreneurship community in the Innovation District build relationships), and of MassApps (a mobile application development competition leveraging public data). Previously, Jeremy was the Co-Founder and Executive Vice President of Business Development for MobileTek Corporation, a developer of PC based applications enabling smarter mobility for consumer mobile devices. Prior to that, Jeremy ran a strategic consulting firm and practiced corporate law with other national law firms in Boston and Los Angeles. Jeremy is a member of or participates at Launchpad Venture Group, Boston Harbor Angels, Golden Seeds, NE Angels, MassChallenge, Web Innovators Group, MassTLC and MobileMondays. For Jeremy's full Nutter bio, click here.